Vyne Therapeutics Stock Target Price and Analyst Consensus
| VYNE Stock | USD 2.95 0.06 2.08% |
The current analyst and expert consensus on Vyne Therapeutics is Strong Buy, with 2 strong buy opinions. The current projected Vyne Therapeutics target price consensus is 16.50 with 3 analyst opinions. Check out Macroaxis Advice on Vyne Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.The most common way Vyne Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Vyne Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Vyne Therapeutics. We encourage you to use your own analysis of Vyne Therapeutics to validate this buy or sell advice. Vyne Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Vyne Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 4.4634.
Lowest Forecast 15.02 | Highest Forecast 18.32 | Target Price 16.5 |
Vyne |
It's important to approach Vyne Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Vyne Therapeutics price targets
Vyne Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Vyne Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Vyne Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Vyne Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Vyne Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Vyne Therapeutics is a key component of Vyne Therapeutics valuation and have some predictive power on the future returns of a Vyne Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested over 90 shares | |
 | Investor Favorites Invested over 40 shares | |
 | Social Domain Invested few shares | |
 | Manufacturing Invested over 30 shares | |
 | Hedge Favorites Invested over 100 shares | |
 | Automobiles and Trucks Invested over 50 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Momentum Invested few shares | |
 | Impulse Invested over 100 shares | |
 | Business Services Invested few shares | |
 | Artificial Intelligence Invested few shares | |
 | FinTech Invested over 40 shares |
Check out Macroaxis Advice on Vyne Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Please note, the presentation of Vyne Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vyne Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vyne Therapeutics' management manipulating its earnings.